Search

Meeting Coverage:

American Academy of Ophthalmology

AAO: 2015

Protocol S

Jeffrey Gross, MD, Scott Krzywonos

Show Description +

Jeffrey Gross, MD, discusses the DRCR.net Protocol S study. Researchers evaluated the safety and efficacy of ranibizumab versus PRP in the treatment of proliferative diabetic retinopathy. PRP has historically been very effective in PDR treatment, but may result in adverse side effects. Dr. Gross details the study's clinical data, explains the differences in results between the two treatments, and says why ranibizumab may be an alternative treatment for PDR.

Posted: 11/17/2015

Keywords:

Proliferative Diabetic Retinopathy (PDR)

•

Protocol S

•

Ranibizumab

•

Retina

•

Therapeutics

•

Retina Subspecialty Day

Up Next

Anti-VEGF with Targeted PRP

Anti-VEGF with Targeted PRP

David M. Brown, MD, Jonathan L. Prenner, MD

Optimum Timing: Pars Plana Vitrectomy

Optimum Timing: Pars Plana Vitrectomy

Caroline Baumal, MD , Richard Kaiser, MD

Potential Treatments for AMD

Potential Treatments for AMD

Thomas Ciulla, MD

YAG Rates: Femto vs Phaco

YAG Rates: Femto vs Phaco

Dan B. Tran, MD, Sonia Manning, MD

An Important Diagnosis: Conjunctival Melanoma

An Important Diagnosis: Conjunctival Melanoma

Carol L. Shields, MD, Mark Kontos, MD

Cross-Linking for Keratoconus

Cross-Linking for Keratoconus

Parag Majmudar MD, Terry Kim, MD

Intraoperative OCT: Impact on Macular Surgery

Intraoperative OCT: Impact on Macular Surgery

Justis Ehlers, MD

A Novel IOL Implant

A Novel IOL Implant

Louis D. Nichamin MD, Mark Kontos, MD

Placing iStents: Potential Challenges

Placing iStents: Potential Challenges

Steven Sarkisian, MD, Steven Vold, MD

Advances With 24-Hour IOP Monitoring

Advances With 24-Hour IOP Monitoring

Kaweh Mansouri, MD, Ranna Jaraha

New Technique for Lens Rescue

New Technique for Lens Rescue

Jonathan L. Prenner, MD, Richard S. Kaiser, MD

$Corneal Refractive Surgery: Impact on Cataract Extraction$

Corneal Refractive Surgery: Impact on Cataract Extraction

Dan B. Tran, MD, Sonia Manning, MD

Role-Playing: Difficult Scenarios

Role-Playing: Difficult Scenarios

Christopher Starr, MD, Neda Shamie, MD

Phakic IOLs: What's Now, What's Next

Phakic IOLs: What's Now, What's Next

Allon Barsam, MB, BS, MA, FRCOphth, Ranna Jaraha

Predictive Modeling for Lens Position

Predictive Modeling for Lens Position

John Davidson, MD, Joseph J.K. Ma, MD, FRCSC

PVR Prevention: Identifying High-Risk Features

PVR Prevention: Identifying High-Risk Features

Jonathan L. Prenner, MD, Richard S. Kaiser, MD

Back to All Videos

Protocol S

Jeffrey Gross, MD, Scott Krzywonos

Jeffrey Gross, MD, discusses the DRCR.net Protocol S study. Researchers evaluated the safety and efficacy of ranibizumab versus PRP in the treatment of proliferative diabetic retinopathy. PRP has historically been very effective in PDR treatment, but may result in adverse side effects. Dr. Gross details the study's clinical data, explains the differences in results between the two treatments, and says why ranibizumab may be an alternative treatment for PDR.

Posted: 11/17/2015

Keywords:

Proliferative Diabetic Retinopathy (PDR)

•

Protocol S

•

Ranibizumab

•

Retina

•

Therapeutics

•

Retina Subspecialty Day

Please log in to leave a comment.

More From AAO: 2015 Coverage

Anti-VEGF with Targeted PRP

Anti-VEGF with Targeted PRP

David M. Brown, MD, Jonathan L. Prenner, MD

Optimum Timing: Pars Plana Vitrectomy

Optimum Timing: Pars Plana Vitrectomy

Caroline Baumal, MD , Richard Kaiser, MD

Potential Treatments for AMD

Potential Treatments for AMD

Thomas Ciulla, MD

YAG Rates: Femto vs Phaco

YAG Rates: Femto vs Phaco

Dan B. Tran, MD, Sonia Manning, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2015.